Temple University / University of Southern California / MD Anderson Cancer Center / Princess Margaret Cancer Center / The Ohio State University / University of Texas / Johns Hopkins University / Roswell Park Cancer Institute / University of Chicago Medical Center / Duke University Medical Center / Fels Institute / Hagop Kantarjian10 Weill Cornell Medical College / /
MedicalCondition
Cancer / Disease / site pain Injection site reaction Decreased appetite Hematuria Contusion Epistaxis / neutropenia Neutropenia Thrombocytopenia Diarrhea Nausea Fatigue / Stand Up To Cancer / /
MusicGroup
Nausea / /
Organization
Princess Margaret Cancer Center / Fels Institute / University of Southern California / Los Angeles / Johns Hopkins University / The Ohio State University / Columbus / Temple University / Philadelphia / Duke University Medical Center / Cornell Medical College / Roswell Park Cancer Institute / USC Keck School of Medicine / University of Texas / University of Chicago Medical Center / /
Person
Sue Naim / Jean Pierre / Eric Feldman / Yong Hao / Karen Yee / Peter Jones / Guillermo Garcia-Manero / Katherine Walsh / Gail J. Roboz / Elizabeth Griffiths / Jean-Pierre Issa / Ellen Ritchie / Aaron Schimmer / Gavin Choy / Raoul Tibes / Jorge Cortes / Mohammad Azab Honorarium / Richard A. Larson / Mayo Clinic Arizona / William Blum / Elias Jabbour / David Rizzieri / Steve Baylin / Wendy Stock / Ruben Mesa / /
DNA demethylation activity over time and safety of 3 different dose-escalation regimens of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in the treatment of relapsed/refractory patients with MDS and AML